Biogen (BIIB) Q2 2026: 73% EPS Beat as Growth Portfolio Takes the Lead
As seen on the 24/7 Wall St. homepage on July 29, 2026.
Biogen's growth portfolio revenue finally surpassed its legacy MS business, propelled by a massive 73% EPS beat and momentum from the Apellis acquisition, prompting a $0.60 full-year guidance raise.
Continue ReadingShow less
Biogen reported Q2 2026 earnings per share of $3.60, well ahead of the $2.07 consensus estimate — a beat of nearly 74%. Revenue came in at $2.74 billion against an estimate of roughly $2.46 billion, a top-line beat of about 11%. The quarter also marked a structural turning point: Biogen's growth portfolio revenue surpassed its legacy multiple sclerosis business for the first time, a milestone the company has been working toward for several years.
The Apellis acquisition contributed to the momentum driving those growth-portfolio results. Management responded to the strong quarter by raising full-year guidance by $0.60, a signal of sustained confidence beyond a single outperforming period.
Disclosure
*$149 for two years (or $1.43 per week) is an introductory promotion for new members only. 62% discount based on the current list price of Stock Advisor of $199/year. Membership will renew at the then-current list price at the end of the membership term. Stock Advisor returns are 930% as compared to the S&P 500 returns of 185% as of April 7, 2026.
The same investor newsletter that told subscribers to buy Amazon in 2002, Netflix in 2004, and Nvidia in 2005 still publishes two new stock picks every month. Over 23 years, Motley Fool's Stock Advisor has more than quadrupled the S&P 500. New members get this month's picks, the Top 10 Rankings, and a 30-day money-back guarantee. Click here to unlock their next top stocks while new members are still being accepted.
Looking at recent history, Biogen's beat pattern has been consistent but uneven in magnitude. The company posted reported EPS of $3.57 in Q1 2026, $1.99 in Q4 2025, and $4.81 in Q3 2025, each ahead of the respective Wall Street estimate. The Q2 2026 beat stands out as the widest margin in that run, making the guidance raise a natural focal point for investors tracking whether the growth portfolio can maintain its new lead over the MS legacy segment.
Mentioned: BIIB